Literature DB >> 1446422

Immunological aspects of pre-eclampsia.

C W Redman1.   

Abstract

The first pregnancy preponderance and apparent partner specificity of pre-eclampsia suggest that it might have an immune aetiology. The pathogenesis of pre-eclampsia is undefined although it is clear that it is a placental disorder. The maternal syndrome appears to be mediated by placental ischaemia secondary to spiral artery insufficiency. This leads to a hypothesis that pre-eclampsia is a two-stage disease. The first comprises processes that limit the size of the spiral arteries (poor placentation) or obstruct them (acute atherosis). Either or both may have immunological causes although there is no direct evidence. Factors limiting placentation could involve maternal immune intolerance of the fetal allograft, which in their most extreme expression could lead to immunologically mediated abortion. Thus pre-eclampsia may be part of a wider spectrum of pregnancy loss secondary to poor maternal immune accommodation of her genetically disparate fetus. The second stage involves the consequences of the ensuing placental ischaemia. The syndrome is currently tentatively ascribed to diffuse maternal endothelial dysfunction. There is less reason to invoke immunological mechanisms in the second stage although neutrophil activation could explain generalized endothelial damage. It should be clear that these conclusions are provisional and that the greatest need is for more investigation to eliminate the uncertainty which clouds our concepts.

Entities:  

Mesh:

Year:  1992        PMID: 1446422     DOI: 10.1016/s0950-3552(05)80012-4

Source DB:  PubMed          Journal:  Baillieres Clin Obstet Gynaecol        ISSN: 0950-3552


  14 in total

Review 1.  Recurrent preterm birth.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Beth L Pineles; Francesca Gotsch; Pooja Mittal; Nandor Gabor Than; Jimmy Espinoza; Sonia S Hassan
Journal:  Semin Perinatol       Date:  2007-06       Impact factor: 3.300

Review 2.  Preeclampsia. Still an enigma.

Authors:  J Duda
Journal:  West J Med       Date:  1996-04

Review 3.  The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia.

Authors:  Langeza Saleh; Koen Verdonk; Willy Visser; Anton H van den Meiracker; A H Jan Danser
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-01-10

4.  Sera from preeclampsia patients elicit symptoms of human disease in mice and provide a basis for an in vitro predictive assay.

Authors:  Satyan Kalkunte; Roland Boij; Wendy Norris; Jennifer Friedman; Zhongbin Lai; Jonathan Kurtis; Kee-Hak Lim; James F Padbury; Leif Matthiesen; Surendra Sharma
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

5.  Placenta in the Critically Ill Mother.

Authors:  Dipali Anand Taggarsi; Bhuvana Krishna
Journal:  Indian J Crit Care Med       Date:  2021-12

Review 6.  Placental Syndromes-A New Paradigm in Perinatology.

Authors:  Katarzyna Kosińska-Kaczyńska
Journal:  Int J Environ Res Public Health       Date:  2022-06-16       Impact factor: 4.614

7.  Extracellular vesicles generated by placental tissues ex vivo: A transport system for immune mediators and growth factors.

Authors:  Wendy Fitzgerald; Nardhy Gomez-Lopez; Offer Erez; Roberto Romero; Leonid Margolis
Journal:  Am J Reprod Immunol       Date:  2018-05-04       Impact factor: 3.886

8.  Myeloid and lymphoid dendritic cells in normal pregnancy and pre-eclampsia.

Authors:  D Darmochwal-Kolarz; J Rolinski; J Tabarkiewicz; B Leszczynska-Gorzelak; J Buczkowski; K Wojas; J Oleszczuk
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

9.  Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father.

Authors:  Louise C Kenny; Douglas B Kell
Journal:  Front Med (Lausanne)       Date:  2018-01-04

Review 10.  Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?

Authors:  Asif Ahmed; Wenda Ramma
Journal:  Br J Pharmacol       Date:  2015-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.